Why This Matters
Clinical and regulatory catalysts can define valuation, financing options, and investor attention for small-cap biotechnology companies.
Phase 2 Readouts
Phase 2 Readouts are among the catalyst types tracked across undercovered healthcare companies. This public page focuses on timing, company, asset, and broad confidence labels.
| Company | Ticker | Catalyst | Timing | Asset | Confidence |
|---|---|---|---|---|---|
| IGC Pharma Inc | IGC | Clinical Trial Completion | 2026-08 | IGC-AD1-Active | Low |
| CervoMed Inc | CRVO | Clinical Trial Completion | 2026-09 | Neflamapimod | Low |
| CDT Equity Inc | CDT | Clinical Trial Completion | 2026-10-20 | Litifilimab | Low |
| Atossa Therapeutics Inc | ATOS | Clinical Trial Completion | 2026-11 | (Z)-endoxifen | Low |
| Kiora Pharmaceuticals Inc | KPRX | Clinical Trial Completion | 2026-11 | KIO-104 | Low |
| Skye Bioscience Inc | SKYE | Clinical Trial Completion | 2026-11-20 | Nimacimab injection | Low |
| BioCardia Inc | BCDA | Clinical Trial Completion | 2026-12 | CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs) | Low |
| Traws Pharma Inc | TRAW | Clinical Trial Completion | 2026-12 | TRX-100 | Low |
| Psyence Biomedical Ltd | PBM | Clinical Trial Completion | 2026-12-30 | Psilocybin therapy | Low |
| Actuate Therapeutics Inc | ACTU | Clinical Trial Completion | 2026-12-31 | FOLFIRNINOX | Low |
| Actinium Pharmaceuticals Inc | ATNM | Clinical Trial Completion | 2026-12-31 | Actinium Ac 225 DOTATATE RYZ101 | Low |
| CalciMedica Inc | CALC | Clinical Trial Completion | 2027-01 | CM4620 | Low |
| Azitra Inc | AZTR | Clinical Trial Completion | 2027-01-15 | ATR04-484 | Low |
| Creative Medical Technology Holdings Inc | CELZ | Clinical Trial Completion | 2027-01-31 | CELZ-201 Administration | Low |
| Grace Therapeutics Inc | GRCE | Clinical Trial Completion | 2027-02 | DISC-3405 | Low |
| Rein Therapeutics Inc | RNTX | Clinical Trial Completion | 2027-02 | DISC-3405 | Low |
| Xilio Therapeutics Inc | XLO | Clinical Trial Completion | 2027-02 | XTX301 | Low |
| Lantern Pharma Inc | LTRN | Clinical Trial Completion | 2027-02-01 | STAR-001 (LP-184) will be administered via IV infusion over 30 (± 5) minutes on Day 1 and Day 8 of each 21-day cycle. | Low |
| Taysha Gene Therapies | TSHA | Clinical Trial Completion | 2027-03-12 | TSHA-101 | Low |
| Telomir Pharmaceuticals Inc | TELO | Clinical Trial Completion | 2027-05 | Zn-Telomir | Low |
| Rein Therapeutics Inc | RNTX | Clinical Trial Completion | 2027-06 | Selinexor 60 mg | Low |
| Sensei Biotherapeutics Inc | SNSE | Clinical Trial Completion | 2027-06 | SNS-101 (anti-VISTA) | Low |
| Cadrenal Therapeutics Inc | CVKD | FDA Meeting | Timing not specified | CAD-1005 | Low |
| Dare Bioscience Inc | DARE | Corporate Update | Timing not specified | n/a | Low |